Assenagon Asset Management
ABUS icon

Assenagon Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Assenagon Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,702
Closed -$121K – 1144
2025
Q3 		$121K Sell
26,702
-12,908
-33% -$47.4K ﹤0.01% 1146
2025
Q2 		$122K Buy
+39,610
New +$132K ﹤0.01% 1132
2024
Q1 		– Sell
-817,574
Closed -$2.04M – 1351
2023
Q4 		$2.04M Hold
817,574
– – 0.01% 915
2023
Q3 		$1.66M Hold
817,574
– – 0.01% 921
2023
Q2 		$1.88M Hold
817,574
– – 0.01% 801
2023
Q1 		$2.48M Hold
817,574
– – 0.01% 761
2022
Q4 		$1.91M Sell
817,574
-1,077,587
-57% -$2.58M 0.01% 828
2022
Q3 		$3.62M Sell
1,895,161
-226,245
-11% -$533K 0.01% 555
2022
Q2 		$5.75M Hold
2,121,406
– – 0.02% 505
2022
Q1 		$6.32M Buy
2,121,406
+2,034,737
+2,348% +$6.23M 0.02% 481
2021
Q4 		$337K Buy
+86,669
New +$337K ﹤0.01% 1276
2021
Q3 		– Sell
-17,851
Closed -$54K – 1272
2021
Q2 		$54K Buy
+17,851
New +$55.3K ﹤0.01% 1174
2020
Q4 		– Sell
-44,362
Closed -$139K – 983
2020
Q3 		$139K Buy
+44,362
New +$135K ﹤0.01% 1086
2019
Q3 		– Sell
-119,800
Closed -$249K – 812
2019
Q2 		$249K Buy
+119,800
New +$306K ﹤0.01% 933

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Assenagon Asset Management's ABUS Position: Q4 2025 in Review

Assenagon Asset Management sold out of Arbutus Biopharma (ABUS) in Q4 2025, closing a stake of 26,702 shares — an estimated $121K sold.

Assenagon Asset Management first reported a position in ABUS in Q2 2019 and held it in 14 quarters. The position peaked at $6.32M in Q1 2022. 172 funds tracked by Wall St. Rank hold ABUS as of Q4 2025.

  • Assenagon Asset Management reported no remaining Arbutus Biopharma position as of Q4 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 26,702 Arbutus Biopharma shares in Q4 2025, an estimated $121K.
  • Assenagon Asset Management first reported a position in Arbutus Biopharma in Q2 2019 and held it in 14 quarters.
  • Assenagon Asset Management's Arbutus Biopharma position peaked at $6.32M in Q1 2022.
  • 172 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2025.

Based on Assenagon Asset Management's 13F filing for Q4 2025, filed 9 Jan 2026.